This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called car…

Relapsed and/or Refractory Multiple Myeloma (RRMM)

~Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07222761

Phase 2

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years a…

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06103838

Phase 1

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Relapsed and/or Refractory Multiple Myeloma

~Estimated

~$10 – $8,750

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06153251